Averting opioid trial, Teva, drug distributors reach last-gasp settlement - The Jerusalem Post
Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid | Reuters.com
Israeli unions warn Teva Pharm over plan to close Ashdod plant
Drugmaker Teva Fueled Opioid Addiction in New York, Jury Finds
Teva Pharmaceutical meets forecasts, but 2023 outlook disappoints | Reuters
Netanyahu asks Teva Pharm to minimize job loss in Israel | Reuters
San Francisco To Start Opioid Epidemic Trial Against Teva, Walgreen: Reuters
CVS Picks Migraine Drugs by Teva, Eli Lilly, Snubs Amgen, Reuters Reports | Ctech
A Drug Company Wagers the U.S. Won't Dare Charge It With Crimes - The New York Times
Opioid lawsuit concerns hit Teva - Globes
Rhode Island takes Teva to trial in multibillion-dollar opioid case | Business Insurance
Teva Pharmaceuticals Slashing 25% of Workforce, Suspending Dividend
TEVA.N) | Stock Price & Latest News | Reuters
Teva Pharmaceuticals to Lay Off 14,000 People
/cloudfront-us-east-2.images.arcpublishing.com/reuters/EDAT5T7QVVOGZP6VRKJB4IAP5E.jpg "Teva, AbbVie finalize $6.6 billion U.S. opioid settlements | Reuters")
Teva, AbbVie finalize $6.6 billion U.S. opioid settlements | Reuters
/cloudfront-us-east-2.images.arcpublishing.com/reuters/32KWZMZCHJLHBO2426REAC4T2I.jpg "Teva to pay up to $4.2 billion in U.S. to settle opioid claims | Reuters")
Teva to pay up to $4.2 billion in U.S. to settle opioid claims | Reuters
Teva reaches proposed $4.35 bln settlement of U.S. opioid lawsuits | Reuters
Teva reaches proposed $4.35 billion settlement of US opioid lawsuits | CNN Business
Incoming Teva CEO Jeremy Levin (front) sits with Teva Chairman Phillip Frost (C) and outgoing CEO Shlomo Yanai during a news conference in Tel Aviv January 2, 2012. Teva Pharmaceutical Industries, the
Teva Names Interim CEO, New Chairman As Vigodman Steps Down
Teva generic medicines hi-res stock photography and images - Alamy
Teva to buy U.S. drug developer Auspex Pharma for $3.5 billion | Reuters.com
Teva Pharmaceutical meets forecasts, but 2023 outlook disappoints | Reuters
Teva Pharm Expects About 25 Percent of EpiPen Market by Year End
Teva Pharma to sell more women's health assets for $1.38 billion | Reuters
Teva To Start Nationwide Settlement Of Opioid Lawsuits From Next Year: Report
